Dambkowski Carl, Chief Medical Officer, has demonstrated a pronounced selling bias in recent insider transactions, as evidenced by SEC Form 4 filings. Over the course of 33 trades, Carl has sold shares totaling approximately $4.48 million, compared to purchases of $916,343. This trend is particularly evident in the most recent activity, with 18 consecutive sell transactions recorded since October 2025. The majority of these sales have been concentrated in APGE, with transactions ranging from smaller amounts like $6,788 on February 4, 2026, to significant sales such as $1,154,478 on January 7, 2026. Notably, Carl’s activity in APGE has included multiple transactions on the same day, such as March 4, 2026, when sales totaled $390,824.75 across three separate filings.
Carl’s trading pattern also includes occasional transactions classified as "M" (discretionary) and "A" (acquisition), though these are minimal compared to the volume of sales. For example, on January 7, 2026, a discretionary transaction of $320,611.50 was reported alongside substantial sales. Additionally, a single transaction involving ORKA on January 23, 2026, was marked as "J" (other), with no associated monetary value. The absence of recent purchases and the consistent liquidation of APGE shares suggest a strategic reduction in holdings. This activity aligns with Carl’s broader trading history, which leans heavily toward divestment rather than accumulation, particularly in APGE.
AI-assisted summary